Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
01 sept. 2022 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick...
Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update
11 août 2022 16h02 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 juil. 2022 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, July 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update
12 mai 2022 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 mai 2022 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, May 02, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update
24 mars 2022 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
- Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study - - Favorable safety profile observed...
Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference
26 janv. 2022 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick...
Bellicum Regains Compliance with Nasdaq Continued Listing Requirements
13 déc. 2021 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has...
Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market
06 déc. 2021 07h30 HE
|
Bellicum Pharmaceuticals, Inc.
- Confirmed partial response observed in one patient in first cohort of metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 - - Favorable safety profile observed in...
Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update
04 nov. 2021 16h05 HE
|
Bellicum Pharmaceuticals, Inc.
- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief...